HomeCompareNICXF vs MRK

NICXF vs MRK: Dividend Comparison 2026

NICXF yields 666.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NICXF wins by $608115.60M in total portfolio value
10 years
NICXF
NICXF
● Live price
666.67%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$608115.66M
Annual income
$469,561,018,816.25
Full NICXF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NICXF vs MRK

📍 NICXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNICXFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NICXF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NICXF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NICXF
Annual income on $10K today (after 15% tax)
$56,666.67/yr
After 10yr DRIP, annual income (after tax)
$399,126,865,993.81/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NICXF beats the other by $399,126,857,665.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NICXF + MRK for your $10,000?

NICXF: 50%MRK: 50%
100% MRK50/50100% NICXF
Portfolio after 10yr
$304057.86M
Annual income
$234,780,514,307.19/yr
Blended yield
77.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NICXF
No analyst data
Altman Z
-14.8
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NICXF buys
0
MRK buys
0
No recent congressional trades found for NICXF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNICXFMRK
Forward yield666.67%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$608115.66M$56.8K
Annual income after 10y$469,561,018,816.25$9,798.13
Total dividends collected$596792.85M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NICXF vs MRK ($10,000, DRIP)

YearNICXF PortfolioNICXF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$77,367$66,666.67$11,206$366.19+$66.2KNICXF
2$564,818$482,035.31$12,650$502.35+$552.2KNICXF
3$3,893,246$3,288,890.67$14,407$694.19+$3.88MNICXF
4$25,352,760$21,186,987.16$16,585$967.82+$25.34MNICXF
5$156,070,781$128,943,327.59$19,342$1,363.89+$156.05MNICXF
6$908,837,800$741,842,064.29$22,913$1,947.19+$908.81MNICXF
7$5,009,769,782$4,037,313,336.56$27,662$2,823.89+$5009.74MNICXF
8$26,159,339,258$20,798,885,591.56$34,159$4,173.35+$26159.31MNICXF
9$129,490,317,125$101,499,824,118.87$43,337$6,308.80+$129490.27MNICXF
10$608,115,658,140$469,561,018,816.25$56,776$9,798.13+$608115.60MNICXF

NICXF vs MRK: Complete Analysis 2026

NICXFStock

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

Full NICXF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NICXF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NICXF vs SCHDNICXF vs JEPINICXF vs ONICXF vs KONICXF vs MAINNICXF vs JNJNICXF vs ABBVNICXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.